ClinicalTrials.gg
CompletedNCT03442569Updated Jul 1, 2025Results posted

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

A Phase 2 interventional study of Panitumumab and Nivolumab in Colon Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 5 sites in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies testing panitumumab in Colonic Neoplasms — 1 open to participants now, 2 under way, 1 of them phase 3. Panitumumab · Colonic Neoplasms.

Enrollment
15th of 21
56 · median 116
Started
2018
the only one that year
Phase 2
15 of 22
none open now
Registered
18th of 22
by date

Among the 22 studies testing panitumumab in Colonic Neoplasms, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 15 in phase 2, and was the 18th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

1 of the 22 studies testing panitumumab in Colonic Neoplasms is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing panitumumab in Colonic Neoplasms, or all of them as a file.
02

Study summary

To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer.

Read the detailed description

The investigators will conduct a single-arm, open-label Phase II clinical trial investigating the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer (mCRC). There will be an initial safety lead-in cohort to ensure the combination is well-tolerated. The primary objective of this study is to estimate the overall response rate in these subjects at 12 weeks . Secondary objectives include the following: estimating the overall response rate in these subjects at 12 weeks by immune-related RECIST criteria (irRECIST), estimating the best response rate by both RECIST 1.1 and irRECIST criteria, estimating progression-free survival (PFS) and duration of response using both RECIST 1.1 and irRECIST criteria, estimating overall survival (OS), and characterizing the safety issues associated with this regimen. Exploratory objectives involve investigating various biomarkers and peripheral blood and tumor assays.

03

Conditions studied

  • Colon Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed colorectal adenocarcinoma, with unresectable or locally advanced disease documented on diagnostic imaging studies.
  2. Previously received 1-2 . Subjects who relapse within 6 months of chemotherapy comprised of oxaliplatin and a fluoropyrimidine will have their adjuvant therapy count as one prior line of therapy.
  3. Confirmed wild-type in KRAS and NRAS codons 12, 13, 59, 61, 117, and 146; and BRAF codon 600, by standard of care testing of tumor specimen. Tissue used for testing may have been collected from primary or metastatic site.
  4. Microsatellite stable as detected by PCR-based assay or CLIA-certified sequencing methodology such as Foundation One; or mismatch repair proficient as detected by immunohistochemistry showing intact nuclear staining of MLH1, MSH2, MSH6, and PMS2
  5. Radiographically present per 1.1
  6. Age ≥ 18 years at the time of consent.
  7. (ECOG) performance status 0 or 1.
  8. Blood counts performed within 3 weeks prior to starting study therapy must have ≥ 1,500/mm3, ≥ 100,000/mm3, and ≥ 9 g/dL.

    *Note: Hematology and other lab parameters that are ≤ grade 2 but still meet criteria for study entry are allowed. Furthermore, changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and/or worsen from baseline during therapy.

  9. Liver function tests performed within 3 weeks prior to starting study therapy must have total ≤ 1.5 x (ULN), and aspartate aminotransferase ≤ 3 x ULN, and albumin ≥ 2.5 g/dL.
  10. Serum creatinine performed within 3 weeks prior to starting study therapy must be ≤ 1.5 x ULN, or have calculated (using Cockcroft-Gault formula provided in Appendix 11.3) of ≥ 50 mL/minute.
  11. Females of must have a negative serum pregnancy test within 24 hours prior to receiving the first dose of study medication. Females of childbearing potential must agree to use 2 methods of effective or abstain from heterosexual sex throughout the treatment period and for 5 months after the last dose of study treatment. Females of childbearing potential are women who have not been surgically sterilized (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or have not been free of menses for >1 year.
  12. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 7 months after the last dose of study treatment.
  13. Written and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  14. An adequate amount of must be available at baseline to be eligible for enrollment in the study. If archival tissue is not available or is inadequate, then the subject must consent to undergo a mandatory biopsy at baseline in order to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Past treatment with an antibody targeting EGFR including cetuximab or panitumumab.
  2. Past treatment with an antibody targeting immune checkpoints including , PD-1, PD-L1, PD-L2, or CD137.
  3. Known untreated or brain metastasis treated within 3 months prior to enrollment in this trial.
  4. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
  5. Has a known additional that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease free for at least five years.
  6. Treatment within 21 days of the first dose of study drug with any other chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or treatment for the treatment of malignancy, or failure to recover from adverse effects of prior therapies administered over 4 weeks prior to Study Day 1. All toxicities from prior therapies must be ≤ Grade 1 (or ≤ Grade 2 for alopecia or peripheral neuropathy). Prior systemic treatment in the setting is allowed. See note above under inclusion 3.1.8
  7. Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining , or compliance to the study procedures.
  8. Pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment. (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  9. History of organ allograft or other history of immunodeficiency, or is receiving systemic therapy or any other form of therapy within 7 days before the first dose of investigational treatment.
  10. Inability or unwillingness to comply with study and/or follow-up requirements.
  11. Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to randomization.
  12. Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to study drug.
  13. Known (HIV), virus (HBV), or virus (HCV) infection. Subjects with laboratory evidence of cleared HBV and HCV infection will be permitted.
  14. Active disease requiring systemic treatment in the past 3 months (for example with disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators, local steroid injections, or inhaled or topical steroids would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study.
  15. Active infection requiring intravenous systemic therapy.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Open-label, single arm, Phase II

    Nivolumab and ipilimumab with panitumumab

    Drug: Panitumumab · Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • 6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab

    Also known as: Vectibix

  • 240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab

    Also known as: Opdivo

  • 1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab

    Also known as: Yervoy

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall Response Rate (ORR) = CR + PR Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions

    Time frame: 12 weeks

Secondary outcomes

  1. Overall Response Rate Per irRECIST

    Overall Response Rate (ORR) = irCR + irPR Per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) for target and/or non-target lesions and assessed by imaging: Complete Response (irCR), Disappearance of all lesions, no new lesions, lymph nodes \< 10 mm in short axis; Partial Response (irPR), ≥30% decrease in the sum of target lesions and non-target lesions are irNN; Stable response (irSD), not meeting criteria for irCR, irPR, or irPD; Progressive Disease (irPD), ≥20% increase in tumor burden and minimum 5 mm absolute increase in compared to nadir; for no new non-target or (irNN) and where irPR or irPD are confirmed by a repeat, consecutive assessment no less than 4 weeks later

    Time frame: 12 weeks

  2. Median Progression Free Survival

    Median Progression Free Survival is the time at which 50% of the study population has experienced disease progression as defined by RECIST, irRECIST, or death from any cause.

    Time frame: Up to 3 years

  3. Median Overall Survival

    Time from the first day of treatment until death from any cause.

    Time frame: Up to 3 years

  4. Median Duration of Response

    Duration of response is the time from documentation of tumor response to disease progression.

    Time frame: Up to 3 years

  5. Toxicity of Treatment

    The number of treatment-emergent grade 3 and 4 toxicities as defined by the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE v4.03) was reported.

    Time frame: Up to 36 month

07

Results

Posted Oct 22, 2021

Participant flow

Subjects were recruited from 5 medical institutions between March 2018 and June 2020.

Participant flow — Overall Study
MilestoneOpen-label, Single Arm, Phase II
Started56
Started treatment55
Completed55
Not completed1
Withdrew: Subject was ineligible after enrollment1

Outcome measures

PrimaryOverall Response Rate

Overall Response Rate (ORR) = CR + PR Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsOpen-label, Single Arm, Phase II
Overall Response Rate32 (21 to 45)
SecondaryOverall Response Rate Per irRECIST

Overall Response Rate (ORR) = irCR + irPR Per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) for target and/or non-target lesions and assessed by imaging: Complete Response (irCR), Disappearance of all lesions, no new lesions, lymph nodes \< 10 mm in short axis; Partial Response (irPR), ≥30% decrease in the sum of target lesions and non-target lesions are irNN; Stable response (irSD), not meeting criteria for irCR, irPR, or irPD; Progressive Disease (irPD), ≥20% increase in tumor burden and minimum 5 mm absolute increase in compared to nadir; for no new non-target or (irNN) and where irPR or irPD are confirmed by a repeat, consecutive assessment no less than 4 weeks later

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Overall Response Rate Per irRECIST
percentage of participantsOpen-label, Single Arm, Phase II
Overall Response Rate Per irRECIST34 (23 to 47)
SecondaryMedian Progression Free Survival

Median Progression Free Survival is the time at which 50% of the study population has experienced disease progression as defined by RECIST, irRECIST, or death from any cause.

Time frame:
Up to 3 years
Reported as:
Median · months
Median Progression Free Survival
monthsOpen-label, Single Arm, Phase II
Median Progression Free Survival6 (5.5 to 7.4)
SecondaryMedian Overall Survival

Time from the first day of treatment until death from any cause.

Time frame:
Up to 3 years
Reported as:
Median · months
Median Overall Survival
monthsOpen-label, Single Arm, Phase II
Median Overall Survival17.4 (14.2 to 27.5)
SecondaryMedian Duration of Response

Duration of response is the time from documentation of tumor response to disease progression.

Time frame:
Up to 3 years
Reported as:
Median · months
Median Duration of Response
monthsOpen-label, Single Arm, Phase II
Median Duration of Response5 (3.3 to 9)
SecondaryToxicity of Treatment

The number of treatment-emergent grade 3 and 4 toxicities as defined by the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE v4.03) was reported.

Time frame:
Up to 36 month
Reported as:
Count of participants · Participants
Toxicity of Treatment
ParticipantsOpen-label, Single Arm, Phase II
Blood and lymphatic system disorders - Other, specify3
Hemolysis1
Myocarditis1
Adrenal insufficiency3
Endocrine disorders - Other, specify1
Abdominal pain2
Colitis1
Colonic obstruction1
Constipation1
Diarrhea3
Gastrointestinal disorders - Other, specify2
Nausea3
Pancreatitis1
Rectal pain1
Small intestinal obstruction1
Vomiting3
Fatigue2
Cholecystitis1
Allergic reaction1
Autoimmune disorder1
Infections and infestations - Other, specify2
Papulopustular rash1
Paronychia1
Rash pustular1
Sepsis2
Soft tissue infection1
Alanine aminotransferase increased3
Aspartate aminotransferase increased3
Lipase increased5
Lymphocyte count decreased4
Neutrophil count decreased1
Platelet count decreased1
Serum amylase increased4
White blood cell decreased2
Anorexia1
Dehydration1
Hyperglycemia1
Hypocalcemia2
Hypokalemia4
Hypomagnesemia8
Hyponatremia1
Hypophosphatemia4
Pain in extremity1
Headache1
Delirium2
Psychiatric disorders - Other, specify1
Acute kidney injury1
Urinary retention1
Dyspnea2
Hypoxia1
Pneumonitis1
Rash acneiform6
Rash maculo-papular3
Skin and subcutaneous tissue disorders - Other, specify1
Stevens-Johnson syndrome1
Surgical and medical procedures - Other, specify1
Hypertension6
Hypotension1
Thromboembolic event2

Adverse events

Collected over From Day 1 of treatment up to 3 years after completion of treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label, Single Arm, Phase II27/56 (48.2%)21/56 (37.5%)56/56 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventOpen-label, Single Arm, Phase II
Adrenal insufficiencyEndocrine disorders3/56
DiarrheaGastrointestinal disorders3/56
Abdominal painGastrointestinal disorders2/56
Aspartate aminotransferase increasedInvestigations2/56
FatigueGeneral disorders2/56
Gastrointestinal disorders - Other, specifyGastrointestinal disorders2/56
Infections and infestations - Other, specifyInfections and infestations2/56
VomitingGastrointestinal disorders2/56
Acute kidney injuryRenal and urinary disorders1/56
Alanine aminotransferase increasedInvestigations1/56
Most frequent other events
Showing 10 of 172
Most frequent other events
EventOpen-label, Single Arm, Phase II
Rash acneiformSkin and subcutaneous tissue disorders51/56
HypomagnesemiaMetabolism and nutrition disorders38/56
PruritusSkin and subcutaneous tissue disorders27/56
FatigueGeneral disorders24/56
HypertensionVascular disorders21/56
Lymphocyte count decreasedInvestigations21/56
NauseaGastrointestinal disorders21/56
VomitingGastrointestinal disorders21/56
Aspartate aminotransferase increasedInvestigations20/56
HypokalemiaMetabolism and nutrition disorders20/56

Baseline characteristics

Age, Customized
Age, Customized(Participants)Open-label, Single Arm, Phase II
Age — 30-391
Age — 40-499
Age — 50-5925
Age — 60-6917
Age — 70-794
Sex: Female, Male
Sex: Female, Male(Participants)Open-label, Single Arm, Phase II
Female19
Male37
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open-label, Single Arm, Phase II
Hispanic or Latino1
Not Hispanic or Latino54
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-label, Single Arm, Phase II
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American7
White44
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Open-label, Single Arm, Phase II
United States56
08

Study locations

5 sites
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27509, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Washington - Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Sep 2020, 30 months.

Results were first posted in Oct 2021, 1 year 1 month after primary completion.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 30 months is below that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Feb 22, 2018
StartActual
Mar 9, 2018
Primary completionActual
Sep 21, 2020
CompletionActual
Dec 2, 2024
Results first posted
Oct 22, 2021
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03442569
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Mar 9, 2018
Primary completion
Sep 21, 2020
Completion
Dec 2, 2024
Results posted
Oct 22, 2021
Last update
Jul 1, 2025

Study contacts

Hanna K Sanoff, MD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · Nivolumab · Ipilimumab

Start the discussion